However, increased plasma BCAAs levels have been observed in some NSCLC patients (Wang Y. et al., 2021), potentially attributable to BCAAs catabolic inhibition by branched-chain keto acid dehydrogenase kinase in NSCLC (Xue et al., 2023). The gene discussed is BCKDK; the disease is non-small cell lung carcinoma.